10-Q: Tactile Systems Q1 2026 Revenue Up 23%, Net Loss Narrows

Tactile Systems Technology reported a 23% increase in Q1 2026 revenue to $75.3 million, driven by strong lymphedema and airway clearance product sales, while net loss narrowed to $1.8 million.

Summary

• Total revenue for the first quarter of 2026 increased by 23% to $75.3 million, up from $61.3 million in the same period of 2025.
• Lymphedema product revenue grew 23% to $62.2 million, and airway clearance product revenue increased 22% to $13.0 million.
• Gross margin improved to 77% from 74% year-over-year.
• Operating expenses increased by 19% to $59.1 million, primarily due to higher sales and marketing, and research and development costs.
• Net loss for the quarter was $1.8 million, an improvement from a net loss of $3.0 million in the first quarter of 2025.
• The company completed the acquisition of LymphaTech, Inc. for approximately $7.2 million in cash plus contingent consideration.
• Cash and cash equivalents stood at $75.0 million as of March 31, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing, with strong revenue growth and improved profitability metrics, offset by continued net losses and increased operating expenses.

Positives

• Revenue increased by 23% to $75.3 million in Q1 2026, driven by strong performance in both lymphedema and airway clearance product lines.
• Gross margin improved to 77% in Q1 2026 from 74% in Q1 2025.
• Net loss decreased to $1.8 million in Q1 2026 from $3.0 million in Q1 2025.
• The company successfully integrated the LymphaTech acquisition, expanding its lymphedema treatment solutions.
• The company remains in compliance with all covenants under its credit agreement.
• No outstanding borrowings under the revolving credit facility as of March 31, 2026.

Negatives

• The company reported a net loss of $1.8 million for the first quarter of 2026.
• Operating expenses increased by 19% to $59.1 million, outpacing revenue growth in some areas.
• Research and development expenses saw a significant increase of 59%.
• Interest income decreased by 26% due to a lower cash balance used for the LymphaTech acquisition.
• The company recorded an income tax expense of $0.9 million in Q1 2026, compared to a tax benefit in the prior year period.

Risks

• Potential for adverse economic conditions, including inflation, rising interest rates, or recession.
• Risks associated with obtaining reimbursement from third-party payers for products.
• Supply chain disruptions, including price increases for supplies and components, and wage inflation.
• Competition from new entrants and existing competitors with new products.
• Compliance with and changes in federal, state, and local government laws and regulations.
• Technological obsolescence or quality issues with products.
• Challenges in expanding the business through strategic acquisitions and integrating acquired businesses.
• Effects of current and future U.S. and foreign trade policy and tariff actions.
• Inability to carry out research, development, and commercialization plans.
• The company is subject to ongoing legal proceedings related to alleged false claims submitted to government payers, with an agreement in principle to settle for approximately $0.6 million plus relators' fees and costs, for which an accrual of $1.0 million was recorded.

Future Outlook

The company believes its cash and cash flows from operations will be sufficient to meet its working capital, capital expenditure, debt repayment, and other cash requirements for at least the next twelve months. Future cash requirements may vary significantly due to factors like economic conditions, sales and marketing investments, operational expansion, IT investments, competitive responses, clinical research costs, interest rate increases, labor and component price inflation, new product development, and potential acquisitions.

Management Comments

• The increase in the lymphedema product line revenue was driven by accelerating commercial momentum from our strong partnerships, execution of our go-to-market commercial strategy and disciplined focus on sales force productivity.
• The increase in the airway clearance product line revenue was primarily driven by strong partnerships and prioritized placement agreements with our top 10 respiratory DME providers.
• IT-related expenses reflected in both R&D expenses and Reimbursement, general and administrative expenses primarily relate to the ongoing implementation of new technology across the entire order process, replacing legacy systems, which we expect to continue through the remainder of 2026.

Industry Context

StockSavvy.ai notes that Tactile Systems Technology's performance aligns with the growing trend of home-based healthcare solutions, driven by the need to control rising healthcare costs. The company's focus on lymphedema and chronic respiratory conditions addresses significant underserved markets. The acquisition of LymphaTech further strengthens its position in the lymphedema space by adding digital monitoring capabilities.

Comparison to Industry Standards

• The company's revenue growth of 23% in Q1 2026 is robust, particularly within the medical device sector, which often experiences more moderate growth rates.
• The improvement in gross margin to 77% is a positive indicator, suggesting efficient cost management relative to sales.
• The net loss, while improved, indicates that the company is still in a growth phase where investments in sales, marketing, and R&D are prioritized over immediate profitability, a common strategy in the medical technology industry.
• Competitors in the pneumatic compression therapy market include companies like DJO Global and Medi, while in the airway clearance market, companies like Philips Respironics and ResMed are key players. Tactile's direct-to-patient model and focus on specific chronic diseases differentiate it.

Legal Proceedings

• Two qui tam complaints filed under seal in May and September 2021 alleging false claims and statements in connection with government payer programs (Medicare, Medicaid, etc.) in violation of the Federal False Claims Act and Federal Anti-Kickback Statute.
• The company reached an agreement in principle to settle these actions for an aggregate payment of approximately $0.6 million, plus relators' attorneys fees and costs.
• An accrual of approximately $1.0 million has been recorded for the settlement, including proposed settlement amount and estimated fees and costs.

Stakeholder Impact

• Shareholders: Positive impact from revenue growth and narrowing net loss, but continued losses and increased operating expenses may temper enthusiasm. Share repurchase program continues.
• Employees: Increased R&D and sales/marketing expenses suggest continued investment in personnel and growth initiatives.
• Customers: Continued focus on improving patient outcomes and quality of life through advanced medical devices.
• Suppliers: Increased inventory levels and purchase commitments suggest ongoing demand and production.

Next Steps

• Continue implementation of new technology across the entire order process through the remainder of 2026.
• Integrate LymphaTech's digital measurement and monitoring platform to expand the care continuum for lymphedema.
• Continue to invest in commercial infrastructure, including sales force, marketing, and reimbursement capabilities.
• Monitor and manage the legal proceedings related to alleged false claims, with an agreement in principle to settle.

Key Dates

Recommendation

The company demonstrates strong revenue growth and improved operational efficiency, leading to a narrowed net loss. However, the continued net loss, significant increase in operating expenses, and ongoing legal proceedings warrant a cautious approach. The strategic acquisition of LymphaTech is a positive step, but its full impact remains to be seen. A 'hold' recommendation reflects the balance of positive growth trends against persistent profitability challenges and legal uncertainties.

Keywords

Tactile Systems Technology, 10-Q, Quarterly Report, Lymphedema, Pneumatic Compression, Airway Clearance, AffloVest, Flexitouch Plus, Nimbl, Medical Devices, Financial Results, Revenue Growth, Net Loss, Acquisition, LymphaTech